KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Esperion Therapeutics (ESPR) over the last 6 years, with Dec 2024 value amounting to $187.2 million.

  • Esperion Therapeutics' Shares Outstanding (Diluted Average) rose 2.98% to $200.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.7 million, marking a year-over-year increase of 2.98%. This contributed to the annual value of $187.2 million for FY2024, which is 81.54% up from last year.
  • As of FY2024, Esperion Therapeutics' Shares Outstanding (Diluted Average) stood at $187.2 million, which was up 81.54% from $103.1 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Shares Outstanding (Diluted Average) registered a high of $187.2 million during FY2024, and its lowest value of $27.5 million during FY2020.
  • In the last 3 years, Esperion Therapeutics' Shares Outstanding (Diluted Average) had a median value of $103.1 million in 2023 and averaged $118.9 million.
  • Data for Esperion Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 129.76% (in 2022) over the last 5 years.
  • Esperion Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $27.5 million in 2020, then increased by 5.20% to $28.9 million in 2021, then spiked by 129.76% to $66.4 million in 2022, then surged by 55.26% to $103.1 million in 2023, then surged by 81.54% to $187.2 million in 2024.